Health-related quality of life and physical activity in children with inherited cardiac arrhythmia or inherited cardiomyopathy: the prospective multicentre controlled QUALIMYORYTHM study rationale, design and methods.


Journal

Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626

Informations de publication

Date de publication:
28 Jul 2021
Historique:
received: 10 04 2021
accepted: 18 07 2021
entrez: 29 7 2021
pubmed: 30 7 2021
medline: 8 9 2021
Statut: epublish

Résumé

Advances in paediatric cardiology have improved the prognosis of children with inherited cardiac disorders. However, health-related quality of life (QoL) and physical activity have been scarcely analysed in children with inherited cardiac arrhythmia or inherited cardiomyopathy. Moreover, current guidelines on the eligibility of young athletes with inherited cardiac disorders for sports participation mainly rely on expert opinions and remain controversial. The QUALIMYORYTHM trial is a multicentre observational controlled study. The main objective is to compare the QoL of children aged 6 to 17 years old with inherited cardiac arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or arrhythmogenic right ventricular dysplasia), or inherited cardiomyopathy (hypertrophic, dilated, or restrictive cardiomyopathy), to that of age and gender-matched healthy subjects. The secondary objective is to assess their QoL according to the disease's clinical and genetic characteristics, the level of physical activity and motivation for sports, the exercise capacity, and the socio-demographic data. Participants will wear a fitness tracker (ActiGraph GT3X accelerometer) for 2 weeks. A total of 214 children are required to observe a significant difference of 7 ± 15 points in the PedsQL, with a power of 90% and an alpha risk of 5%. After focusing on the survival in children with inherited cardiac disorders, current research is expanding to patient-reported outcomes and secondary prevention. The QUALIMYORYTHM trial intends to improve the level of evidence for future guidelines on sports eligibility in this population. Trial registration ClinicalTrials.gov Identifier: NCT04712136, registered on January 15th, 2021 ( https://clinicaltrials.gov/ct2/show/NCT04712136 ).

Sections du résumé

BACKGROUND BACKGROUND
Advances in paediatric cardiology have improved the prognosis of children with inherited cardiac disorders. However, health-related quality of life (QoL) and physical activity have been scarcely analysed in children with inherited cardiac arrhythmia or inherited cardiomyopathy. Moreover, current guidelines on the eligibility of young athletes with inherited cardiac disorders for sports participation mainly rely on expert opinions and remain controversial.
METHODS METHODS
The QUALIMYORYTHM trial is a multicentre observational controlled study. The main objective is to compare the QoL of children aged 6 to 17 years old with inherited cardiac arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or arrhythmogenic right ventricular dysplasia), or inherited cardiomyopathy (hypertrophic, dilated, or restrictive cardiomyopathy), to that of age and gender-matched healthy subjects. The secondary objective is to assess their QoL according to the disease's clinical and genetic characteristics, the level of physical activity and motivation for sports, the exercise capacity, and the socio-demographic data. Participants will wear a fitness tracker (ActiGraph GT3X accelerometer) for 2 weeks. A total of 214 children are required to observe a significant difference of 7 ± 15 points in the PedsQL, with a power of 90% and an alpha risk of 5%.
DISCUSSION CONCLUSIONS
After focusing on the survival in children with inherited cardiac disorders, current research is expanding to patient-reported outcomes and secondary prevention. The QUALIMYORYTHM trial intends to improve the level of evidence for future guidelines on sports eligibility in this population. Trial registration ClinicalTrials.gov Identifier: NCT04712136, registered on January 15th, 2021 ( https://clinicaltrials.gov/ct2/show/NCT04712136 ).

Identifiants

pubmed: 34321045
doi: 10.1186/s12955-021-01825-6
pii: 10.1186/s12955-021-01825-6
pmc: PMC8317438
doi:

Substances chimiques

Oxygen S88TT14065

Banques de données

ClinicalTrials.gov
['NCT04712136']

Types de publication

Controlled Clinical Trial Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

187

Subventions

Organisme : Centre Hospitalier Régional Universitaire de Montpellier
ID : AOI 2019 young researcher award
Organisme : Direction Générale de l'offre de Soins
ID : GIRCI-SOHO-APITHEM-2019
Organisme : Fédération Française de Cardiologie
ID : AAP FFC 2019
Organisme : Cardiogen
ID : 2018 Call for proposal

Informations de copyright

© 2021. The Author(s).

Références

Med Care. 2001 Aug;39(8):800-12
pubmed: 11468499
J Pediatr Endocrinol Metab. 2017 Aug 28;30(8):863-868
pubmed: 28753541
Presse Med. 2017 May;46(5):530-537
pubmed: 28126509
Pediatrics. 2006 Sep;118(3):e586-93
pubmed: 16950950
J Am Heart Assoc. 2017 Sep 21;6(9):
pubmed: 28935680
Eur Heart J. 2021 Jan 1;42(1):17-96
pubmed: 32860412
Arch Cardiovasc Dis. 2020 Dec;113(12):811-820
pubmed: 33069639
J Appl Physiol (1985). 1985 Jul;59(1):211-7
pubmed: 4030564
Eur J Cardiothorac Surg. 2013 Jun;43(6):1096-100
pubmed: 23345176
Int J Cardiol. 2017 Dec 1;248:216-220
pubmed: 28823501
Arch Cardiovasc Dis. 2018 Mar;111(3):180-188
pubmed: 29100908
Br J Sports Med. 2011 May;45(6):498-503
pubmed: 19679577
Eur J Prev Cardiol. 2012 Oct;19(5):1034-65
pubmed: 23126001
J Am Coll Cardiol. 2018 May 29;71(21):2434-2446
pubmed: 29793633
Int J Cardiol. 2019 Jun 15;285:86-92
pubmed: 30857849
Int J Cardiol. 2016 Jan 15;203:1052-60
pubmed: 26638054
Pediatr Cardiol. 2016 Feb;37(2):217-24
pubmed: 26396114
Circulation. 2004 Jun 8;109(22):2807-16
pubmed: 15184297
Health Qual Life Outcomes. 2020 Nov 12;18(1):366
pubmed: 33183312
Circ Arrhythm Electrophysiol. 2013 Oct;6(5):939-45
pubmed: 23994883
Eur Heart J. 2005 Jul;26(14):1422-45
pubmed: 15923204
Qual Health Res. 2011 Feb;21(2):278-91
pubmed: 20935236
Pediatr Cardiol. 2015 Dec;36(8):1588-601
pubmed: 26024647
Chest. 1992 Feb;101(2):485-9
pubmed: 1735277
Eur Heart J. 2020 Nov 14;41(43):4191-4199
pubmed: 32845299
Circ Arrhythm Electrophysiol. 2018 Nov;11(11):e006305
pubmed: 30520349
Arch Dis Child. 2020 Dec;105(12):1167-1174
pubmed: 32732318
J Health Psychol. 2019 Mar;24(3):386-396
pubmed: 27872385
Circulation. 2013 May 28;127(21):2147-59
pubmed: 23630128
BMC Med Genet. 2010 Feb 17;11:27
pubmed: 20163700
Am J Cardiol. 2016 Feb 15;117(4):605-610
pubmed: 26721659
Eur Heart J. 2014 Aug 7;35(30):2001-9
pubmed: 24904027
Cardiol Young. 2020 May;30(5):692-697
pubmed: 32286207
J Cardiovasc Nurs. 2020 May/Jun;35(3):300-306
pubmed: 31904691
Paediatr Child Health. 2009 Mar;14(3):167-70
pubmed: 20190897
Br J Sports Med. 2013 Jan;47(1):28-33
pubmed: 23193325
Adv Exp Med Biol. 2017;999:257-268
pubmed: 29022267
J Cardiopulm Rehabil Prev. 2017 Jul;37(4):239-249
pubmed: 27428818
Can J Cardiol. 2015 Feb;31(2):117-23
pubmed: 25573090
J Pediatr. 2016 Mar;170:173-80.e1-4
pubmed: 26725459
Eur Heart J. 2015 Nov 1;36(41):2793-2867
pubmed: 26320108
Clin Cardiol. 2015 May;38(5):323-6
pubmed: 25955277
J Appl Physiol Respir Environ Exerc Physiol. 1984 Mar;56(3):628-34
pubmed: 6706770
Arrhythm Electrophysiol Rev. 2018 Aug;7(3):187-192
pubmed: 30416732
Cardiol Young. 2017 Jan;27(S1):S43-S48
pubmed: 28084960
Compr Physiol. 2012 Apr;2(2):1143-211
pubmed: 23798298
Int J Cardiol. 2018 Jan 15;251:34-41
pubmed: 29107358
Rev Epidemiol Sante Publique. 1998 Feb;46(1):49-55
pubmed: 9533234
J Appl Physiol (1985). 1986 Jun;60(6):2020-7
pubmed: 3087938
J Am Coll Cardiol. 2015 Dec 1;66(21):2424-2428
pubmed: 26542662
J Appl Physiol (1985). 2020 Nov 1;129(5):1102-1110
pubmed: 32909919
Circulation. 2019 Apr 16;139(16):1889-1899
pubmed: 30813762
Heart. 2018 Jun;104(12):1026-1036
pubmed: 29170358
Arch Cardiovasc Dis. 2015 Nov;108(11):589-97
pubmed: 26365479
Pharmacoeconomics. 2001;19(2):187-95
pubmed: 11284382
Health Qual Life Outcomes. 2021 Mar 4;19(1):75
pubmed: 33663527
Int J Cardiol. 2019 May 15;283:112-118
pubmed: 30616811

Auteurs

Pascal Amedro (P)

Department of Paediatric and Adult Congenital Cardiology, M3C National Reference Centre, Haut-Lévêque Cardiology Hospital, Bordeaux University Hospital, Avenue de Magellan, 33604, Pessac Cedex, France. pascal.amedro@gmail.com.
INSERM, Bordeaux Cardio-Thoracic Research Centre, U1045, University of Bordeaux, Pessac, France. pascal.amedro@gmail.com.
IHU Liryc, Electrophysiology and Heart Modelling Institute, Fondation Bordeaux Université, Pessac, France. pascal.amedro@gmail.com.

Oscar Werner (O)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.

Hamouda Abassi (H)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.
PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France.

Aymeric Boisson (A)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.

Luc Souilla (L)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.

Sophie Guillaumont (S)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.
Paediatric Cardiology and Rehabilitation Unit, Institut-Saint-Pierre, Palavas-Les-Flots, France.

Johanna Calderon (J)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.
PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France.

Anne Requirand (A)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.

Marie Vincenti (M)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.
PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France.

Victor Pommier (V)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.
Paediatric Cardiology and Rehabilitation Unit, Institut-Saint-Pierre, Palavas-Les-Flots, France.

Stefan Matecki (S)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.
PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France.

Gregoire De La Villeon (G)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.
Paediatric Cardiology and Rehabilitation Unit, Institut-Saint-Pierre, Palavas-Les-Flots, France.

Kathleen Lavastre (K)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, Montpellier University Hospital, Montpellier, France.

Alain Lacampagne (A)

PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France.

Marie-Christine Picot (MC)

Epidemiology and Clinical Research Department, Montpellier University Hospital, Montpellier, France.

Constance Beyler (C)

Paediatric Cardiology and Physiology Department, Robert Debré University Hospital, University of Paris, AP-HP, Paris, France.

Christophe Delclaux (C)

Paediatric Cardiology and Physiology Department, Robert Debré University Hospital, University of Paris, AP-HP, Paris, France.

Yves Dulac (Y)

Paediatric Cardiology Department, M3C Regional Reference Centre, Toulouse University Hospital, Toulouse, France.

Aitor Guitarte (A)

Paediatric Cardiology Department, M3C Regional Reference Centre, Toulouse University Hospital, Toulouse, France.

Philippe Charron (P)

Department of Cardiology, National Reference Centre for Inherited Cardiomyopathy, University of Paris, AP-HP, Paris, France.

Isabelle Denjoy-Urbain (I)

Department of Cardiology, National Reference Centre for Inherited Cardiomyopathy, University of Paris, AP-HP, Paris, France.

Vincent Probst (V)

Department of Cardiology, National Reference Centre for Inherited Cardiac Arrhythmia, L'institut du thorax, INSERM, CNRS, University of Nantes, Nantes University Hospital, Nantes, France.

Alban-Elouen Baruteau (AE)

Department of Pediatric Cardiology and Pediatric Cardiac Surgery, L'Institut du Thorax, INSERM, CNRS, University of Nantes, Nantes University Hospital, Nantes, France.

Philippe Chevalier (P)

Department of Congenital Cardiology, National Reference Centre for Inherited Cardiac Arrhythmia, University of Lyon, Lyon University Hospital, Lyon, France.

Sylvie Di Filippo (S)

Department of Congenital Cardiology, National Reference Centre for Inherited Cardiac Arrhythmia, University of Lyon, Lyon University Hospital, Lyon, France.

Jean-Benoit Thambo (JB)

Department of Paediatric and Adult Congenital Cardiology, M3C National Reference Centre, Haut-Lévêque Cardiology Hospital, Bordeaux University Hospital, Avenue de Magellan, 33604, Pessac Cedex, France.
INSERM, Bordeaux Cardio-Thoracic Research Centre, U1045, University of Bordeaux, Pessac, France.
IHU Liryc, Electrophysiology and Heart Modelling Institute, Fondation Bordeaux Université, Pessac, France.

Damien Bonnet (D)

Paediatric Cardiology Department, Necker-Enfants malades, M3C National Reference Centre, University of Paris, AP-HP, Paris, France.

Jean-Luc Pasquie (JL)

Cardiology Department of Cardiology, Regional Reference Centre for Inherited Cardiac Arrhythmia, Montpellier University Hospital, Montpellier, France.
PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH